Vancouver, British Columbia – (October 24^th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) a leading liquid biopsy company focusing on metabolomics for the early diagnosis of hard to detect and treat cancers is pleased to announce today that its abstract has been accepted for poster presentation at the upcoming San Antonio Brest Cancer Symposium (SABCS) taking place December 5-9, 2023 in San Antonio, Texas.

The abstract entitled “Early Detection of Breast Cancer using Targeted Plasma Metabolomic Profiling” will be presented during the Spotlight Poster Session 5 on Friday, December 8, 2023, Time: 12:00 PM – 2:00 PM at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

“We are delighted to be invited to present our latest exciting data at this seminal breast cancer event. The San Antonio Breast Cancer Symposium is the largest international breast cancer congress focused on clinical, translational, and basic research. The specialized focus provides an intimate setting for discussions between key opinion leaders, clinicians, and analysts leading to unique insight into landscape-altering clinical data. BioMark’s early breast cancer study data further demonstrates the ability of its AI-driven metabolomics platform to be versatile and useful for the early diagnosis of various cancers,” said Rashid Bux CEO and President of BioMark. In addition, the BioMark team has been invited to meet various groups from existing collaborating partners and analysts.

Breast cancer (BC) is the second leading cause of cancer death among women. Accordingly, early diagnosis is key to the successful treatment, management, and care of BC. Our study identified and validated a simple, high-performing, metabolite-based test for the early detection of BC. These findings could provide the foundations for the development of a routine blood-based test for women at the highest risk for BC that is cost-effective, accurate, and reliable. In addition, this approach could be used to complement other modalities, especially for BC patients with dense breasts.

Mr. Bux further adds, “Over the past 12 months, the company continues to make significant developments in accelerating the commercialization of its early lung cancer blood-based cancer, as well as establishing a broader platform that can play an integral part in managing other cancers. Furthermore, the company has been investing and integrating more advanced data analytics tools to extract valuable insights from data, empowering healthcare professionals to make informed decisions and improve patient care”.

The Company’s scientific team and senior management will be present at the event to discuss the latest clinical results of its early breast cancer liquid biopsy assay. The poster will be available on our website following the conclusion of the meeting. Interested parties may also request, in advance, a meeting with senior management at [email protected].

About BioMark Diagnostics Inc.

BioMark is a leading liquid biopsy company developing a molecular diagnostics technology platform that leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. While the Company’s current focus is on the commercialization of its liquid biopsy test for early detection of lung, it has a plan to expand into other hard-to-detect and treat cancers such as brain, ovarian, and pancreatic.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.

For further information on BioMark, please Contact:

Rashid Ahmed Bux, President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779, Email: [email protected]

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved the content of this press release.